Xeris Biopharma Holdings (XERS) Other Non-Current Assets (2020 - 2026)

Xeris Biopharma Holdings has reported Other Non-Current Assets for 7 years, with the latest figure at $5.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets changed 0.47% year-over-year to $5.1 million; the trailing twelve-month figure through Mar 2026 stood at $5.1 million (changed 0.47% YoY), and the FY2025 full-year result was $5.2 million, down 3.46% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $5.1 million, down from $5.2 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $5.5 million in Q2 2024, with the low at $2.2 million in Q3 2022.
• Historically, Other Non-Current Assets has averaged $4.5 million across 5 years, with a median of $4.8 million in 2023.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 928.44% — and 2025, when it retreated 7.86%.
• Xeris Biopharma Holdings' Other Non-Current Assets stood at $4.7 million in 2022, then dropped by 4.02% to $4.5 million in 2023, then rose by 19.1% to $5.4 million in 2024, then retreated by 3.46% to $5.2 million in 2025, then fell by 1.88% to $5.1 million in 2026.
• The last three Other Non-Current Assets figures came in at $5.1 million (Q1 2026), $5.2 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.